Avastin/Tarceva Combo Fails In Second-Line NSCLC
This article was originally published in The Pink Sheet Daily
Industry analysts see little consequence, as each is already well-positioned in lung cancer.
You may also be interested in...
EPS misses consensus, but sales of most products modestly estimates.
CHICAGO - First placebo-controlled, double-blinded evidence for bevacizumab in first-line metastatic breast cancer presented at ASCO.
SATURN should provide more clues on KRAS as efficacy biomarker, CEO says.